Welcome to our dedicated page for Biote SEC filings (Ticker: BTMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Revenue per pellet, certification fees, and HIPAA compliance notes are buried deep in Biote Corp’s disclosures. If you have ever opened a 300-page report asking, “How do I track Biote insider trading Form 4 transactions or locate clinical segment margins?” you already know the challenge.
Stock Titan solves it. Our AI-powered summaries break down every filing type the moment it hits EDGAR—whether it’s a Biote annual report 10-K simplified, the latest Biote quarterly earnings report 10-Q filing, or an unexpected Biote 8-K material events explained. Need executive pay details? The Biote proxy statement executive compensation section is auto-tagged. Monitoring ownership changes? Get Biote Form 4 insider transactions real-time alerts and see a concise table of each director’s moves. Our coverage includes:
- 10-K & 10-Q AI insights that highlight practitioner-count growth and pellet revenue trends.
- Form 4 dashboards for Biote executive stock transactions Form 4.
- Instant notifications when new exhibits surface in an 8-K.
Beyond raw documents, you receive context: ratios that flag margin shifts in practice-building services, comparisons to prior quarters, and compliance risk call-outs—everything an investor needs for understanding Biote SEC documents with AI. Stop scrolling through PDFs; start reading concise Biote earnings report filing analysis and make decisions faster. Real-time updates, expert commentary, and a complete archive of Biote SEC filings explained simply—all in one place.
biote Corp. (BTMD) reported a return to profitability for the quarter ended June 30, 2025 while carrying meaningful leverage and ongoing contingent liabilities. Total revenue for the quarter was $48.9 million (product revenue $47.7M), roughly flat year-over-year, and operating income improved to $10.8 million from $6.2M a year earlier. Net income for the quarter was $3.9 million and net income attributable to Biote stockholders was $3.2 million (basic EPS $0.10), reversing prior-year losses. For the six months, net income was $19.8 million and revenue totaled $97.9 million.
On the balance sheet, cash declined to $19.6 million from $39.3M at year-end and total assets fell to $104.8 million. Total liabilities remained elevated at $183.6 million, leaving a stockholders' deficit attributable to Biote of $85.1 million. The company remains in compliance with its credit covenants on a Term Loan that matures in May 2027. Significant items in the period include a $8.9 million mark-to-market gain on earnout liabilities and settlement activity that reduced share repurchase liabilities following a $25.1M repurchase payment.
FAQ
What is the current stock price of Biote (BTMD)?
What is the market cap of Biote (BTMD)?
